Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach

Journal of Viral Hepatitis

Volumn 25, Issue 1, 2018, Pages 4-9

  Naylor, P H ^a   Mutchnick, M G ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hepatitis B treatment; thymosin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; PLACEBO; TENOFOVIR; THYMOSIN ALPHA1; ANTIVIRUS AGENT; IMMUNOLOGICAL ADJUVANT; THYMOSIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INJECTION SITE PAIN; NONHUMAN; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROCONVERSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; CHRONIC HEPATITIS B; COMBINATION DRUG THERAPY; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY; THYMOSIN; TREATMENT OUTCOME;

EID: 85034647294     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12807     Document Type: Review

References (40)

1. Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol. 2015;7:1541-1552.
2. Sundaram V, Kowdley K. Management of chronic hepatitis B infection. BMJ. 2015;351:h4263.
3. Tang C-M, Yau TO, Yu J. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol. 2014;28:6262-6278.
4. Naylor PH, Mutchnick MG. Thymus-derived peptides in the treatment of viral chronic hepatitis. Dig Dis. 1996;14:362-370.
5. Wu X, Jai J, You H. Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opin Biol Ther. 2015;15(Suppl 1):S129-S132.
6. Lok AS, McMahon BJ, Brown Jr RS, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63:284-306.
7. Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology. 2015;61:712-721.
8. Petersen J, Dandri M. Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy? Liver Int. 2015;35(Suppl 1):114-120.
9. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa 2a HBeAg-positive chronic Hepatitis B study group. Peginterferon alfa 2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682-2695.
10. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa 2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206-1217.
11. Marcellin P, Ahn SH, Ma X, et al., Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology. 2016;150:134-144.
12. Brouwer WP, Xie Q, Sonneveld MJ, et al. Adding Peginterferon to entecavir increases response rates in HBeAg-positive CHB patients: week 96 results of a global multicenter randomised trial (ARES study). J Hepatol. 2014;60:S2.
13. Xie Q, Zhou H, Bai X, et al. A randomized, open-label clinical study of combined Peginterferon alfa-2a (40kD) and entecavir treatment for HBeAg-positive chronic hepatitis B. Clin Infect Dis. 2014;000:000.
14. Garaci E, Pica F, Matteucci C, et al. Historical review on thymosin α1 in oncology: preclinical and clinical experiences. Expert Opin Biol Ther. 2015;15(Suppl 1):S31-S39.
15. Naylor PH, Goldstein AL. Thymosin modulates immune and endocrine events. Prog Clin Biol Res. 1988;256:489-502.
16. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009 May;9:593-608.
17. Tuthill C, Rios I, McBeath R. Thymosin alpha 1: past clinical experience and future promise. Ann N Y Acad Sci. 2010;1194:130-135.
18. Liaw YF. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004;19:S73-S75.
19. Sztein M, Serrate S. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol. 1989;11:789-800.
20. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103:4232-4239.
21. Zhang P, Chan J, Dragoi AM, et al. Activation of IKK by thymosin alpha1 requires the TRAF6 signalling pathway. EMBO Rep. 2005;6:531-537.
22. Baumann CA, Badamchian M, Goldstein AL. Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kiNUCse C dependent second messenger pathways. Mech Age Develop. 1997;94:85-101.
23. Matteucci C, Minutolo A, Sinibaldi-Vallebona P, et al. Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1. Ann N Y Acad Sci. 2010;1194:6-19.
24. Gerin JL, Korba BE, Cote PJ, Tennant BC. A preliminary report of a controlled study of thymosin alpha 1 in the woodchuck model of hepadnavirus infection. In: Block T, ed. Innovations in Antiviral Development and the Detection of Virus Infection. Jefferson Medical: Philadelphia, PA; 1992:121-123.
25. Tennant BC, Korba BE, Baldwin BH, Goddard LA, Hornbuckle WE, Cote PJ. Treatment of chronic woodchuck hepatitis virus infection with thymosin alpha-1 (TΑ1). Antiviral Res. 1993;20(suppl 1):163.
26. Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991;14:409-415.
27. Mutchnick MG, Lindsay KL, Schiff ER, et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat. 1999;6:397-403.
28. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998;27:1383-1387.
29. Andreone P, Cursaro C, Gramenzi A, et al. A randomized controlled trial of thymosin alpha 1 versus interferon alpha treatment in patients with hepatitis B e antigen antibody and hepatitis B virus DNA positive chronic hepatitis B. Hepatology. 1996;24:774-777.
30. Chan HL, Tang J-L, Tam W, Sung JJ-Y. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Theer. 2001;15:1899-1905.
31. Yang YF, Zahn W, Zhong YD, et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta analysis. Antiviral Res. 2008;77:136-141.
32. Rasi G, Mutchnick MG, Di Virgilio D, et al. Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy alpha 1 therapy in the treatment of chronic hepatitis B. J Viral Hepat. 1996;3:191-196.
33. Saruc M, Ozden N, Turkel N, et al. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J Pharm Sci. 2003;92:1386-1389.
34. Lim SG, Wai CT, Lee YM, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11:245-253.
35. You J, Zhuang L, Cheng HY, et al. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol. 2006;12:6715-6721.
36. Song EY, Shin Y, Roh EY, et al. Serum HBsAg levels during peginterferon α-2a treatment with or without thymosin α-1 in HBeAg-positive chronic hepatitis B patients. J Med Virol. 2011;83:88-94.
37. Kim BH, Lee YJ, Kim W, et al. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study. Scand J Gastroenterol. 2012;47:1048-1055.
38. Mao HY, Shi TD. Treatment with interferon and thymosin alpha 1 vs interferon monotherapy for HBeAg positive chronic hepatitis b: a meta-analysis. Zhonghua Gan Zang Bing AzAhi. 2011;19:29-33.
39. Zhang Yuan-Yuan, Chen En-Qiang, Yang Jin, Duan Yu-Rong, Tang Hong. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J. 2009;6:63.
40. Qu Y, Tian Z, Bao X, Lyu Y, Lyu J. Entecavir versus entecavir-thymosin alpha-1 combination therapy for chronic hepatitis B: a meta analysis. Mod J Integr Tradit Chin West Med. 2015;9:913-916.